Thursday, December 13, 2012
Publication and contact
Alzheimer's disease (AD)
Patient sample and mouse
studies suggest inhibiting IL-12 and IL-23 signaling could help treat AD. In
a transgenic mouse model of AD, microglia production of p40,
a subunit common to IL-12 and IL-23, was greater than that in healthy
controls. In the same mouse model, intracerebroventricular delivery of an
anti-p40 antibody decreased cognitive deficits and b-amyloid
compared with delivery of an isotype control. In cerebrospinal fluid samples
from patients with AD, p40 levels were higher than those in samples from
healthy controls. Next steps include studying the downstream effects and
mechanisms related to targeting p40.
Bristol-Myers Squibb Co.
& Johnson market Stelara
ustekinumab, a human mAb that inhibits IL-12 and IL-23, to treat psoriasis.
Laboratories' briakinumab, a human mAb against IL-12
and IL-23, is under regulatory review for the same indication.
At least four other companies have compounds targeting both IL-12 and IL-23
in Phase II testing or earlier to treat various autoimmune or inflammatory
Published online Dec. 13, 2012
Patent application filed;
available for licensing from Unitectra
via the University
Vom Berg, J. et al. Nat.
Med.; published online Nov. 25, 2012;
Contact: Frank L. Heppner, Charité-University Hospital
Berlin, Berlin, Germany
Contact: Burkhard Becher, University of Zurich, Zurich,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]